Switch to:
Also traded in: France, Germany, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 8.40
IPSEY's Cash to Debt is ranked higher than
67% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. IPSEY: 8.40 )
Ranked among companies with meaningful Cash to Debt only.
IPSEY' s Cash to Debt Range Over the Past 10 Years
Min: 0.1  Med: 8.40 Max: 56.44
Current: 8.4
0.1
56.44
Equity to Asset 0.62
IPSEY's Equity to Asset is ranked lower than
51% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. IPSEY: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
IPSEY' s Equity to Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.62 Max: 0.66
Current: 0.62
0.28
0.66
F-Score: 9
Z-Score: 5.57
M-Score: -2.75
WACC vs ROIC
6.79%
18.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 16.62
IPSEY's Operating margin (%) is ranked higher than
74% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. IPSEY: 16.62 )
Ranked among companies with meaningful Operating margin (%) only.
IPSEY' s Operating margin (%) Range Over the Past 10 Years
Min: 6  Med: 16.52 Max: 21.02
Current: 16.62
6
21.02
Net-margin (%) 11.52
IPSEY's Net-margin (%) is ranked higher than
68% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. IPSEY: 11.52 )
Ranked among companies with meaningful Net-margin (%) only.
IPSEY' s Net-margin (%) Range Over the Past 10 Years
Min: -2.19  Med: 13.02 Max: 15.29
Current: 11.52
-2.19
15.29
ROE (%) 15.07
IPSEY's ROE (%) is ranked higher than
72% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. IPSEY: 15.07 )
Ranked among companies with meaningful ROE (%) only.
IPSEY' s ROE (%) Range Over the Past 10 Years
Min: -2.92  Med: 16.33 Max: 30
Current: 15.07
-2.92
30
ROA (%) 9.36
IPSEY's ROA (%) is ranked higher than
75% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. IPSEY: 9.36 )
Ranked among companies with meaningful ROA (%) only.
IPSEY' s ROA (%) Range Over the Past 10 Years
Min: -1.75  Med: 9.88 Max: 15.26
Current: 9.36
-1.75
15.26
ROC (Joel Greenblatt) (%) 56.32
IPSEY's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. IPSEY: 56.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IPSEY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 18.32  Med: 55.88 Max: 132.84
Current: 56.32
18.32
132.84
Revenue Growth (3Y)(%) 3.80
IPSEY's Revenue Growth (3Y)(%) is ranked lower than
58% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. IPSEY: 3.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IPSEY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.4  Med: 4.45 Max: 5.8
Current: 3.8
-1.4
5.8
EBITDA Growth (3Y)(%) 23.50
IPSEY's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. IPSEY: 23.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IPSEY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.9  Med: -0.75 Max: 23.5
Current: 23.5
-15.9
23.5
EPS Growth (3Y)(%) 28.70
IPSEY's EPS Growth (3Y)(%) is ranked higher than
80% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. IPSEY: 28.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IPSEY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -78.3  Med: -14.45 Max: 28.7
Current: 28.7
-78.3
28.7
» IPSEY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with IPSEY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.54
IPSEY's P/E(ttm) is ranked higher than
53% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.80 vs. IPSEY: 26.54 )
Ranked among companies with meaningful P/E(ttm) only.
IPSEY' s P/E(ttm) Range Over the Past 10 Years
Min: 0.13  Med: 20.60 Max: 2433
Current: 26.54
0.13
2433
PE(NRI) 26.54
IPSEY's PE(NRI) is ranked higher than
54% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.83 vs. IPSEY: 26.54 )
Ranked among companies with meaningful PE(NRI) only.
IPSEY' s PE(NRI) Range Over the Past 10 Years
Min: 0.14  Med: 21.05 Max: 33.04
Current: 26.54
0.14
33.04
P/B 3.81
IPSEY's P/B is ranked lower than
70% of the 936 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. IPSEY: 3.81 )
Ranked among companies with meaningful P/B only.
IPSEY' s P/B Range Over the Past 10 Years
Min: 1.53  Med: 3.05 Max: 4.81
Current: 3.81
1.53
4.81
P/S 2.87
IPSEY's P/S is ranked lower than
54% of the 937 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.68 vs. IPSEY: 2.87 )
Ranked among companies with meaningful P/S only.
IPSEY' s P/S Range Over the Past 10 Years
Min: 1.26  Med: 2.48 Max: 3.81
Current: 2.87
1.26
3.81
PFCF 25.27
IPSEY's PFCF is ranked higher than
62% of the 465 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.80 vs. IPSEY: 25.27 )
Ranked among companies with meaningful PFCF only.
IPSEY' s PFCF Range Over the Past 10 Years
Min: 10.08  Med: 21.94 Max: 46.82
Current: 25.27
10.08
46.82
POCF 16.57
IPSEY's POCF is ranked higher than
67% of the 631 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.19 vs. IPSEY: 16.57 )
Ranked among companies with meaningful POCF only.
IPSEY' s POCF Range Over the Past 10 Years
Min: 6.62  Med: 13.27 Max: 20.67
Current: 16.57
6.62
20.67
EV-to-EBIT 18.21
IPSEY's EV-to-EBIT is ranked higher than
58% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.51 vs. IPSEY: 18.21 )
Ranked among companies with meaningful EV-to-EBIT only.
IPSEY' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 15.00 Max: 25.9
Current: 18.21
8.7
25.9
EV-to-EBITDA 14.84
IPSEY's EV-to-EBITDA is ranked higher than
59% of the 847 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.31 vs. IPSEY: 14.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
IPSEY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 11.40 Max: 18.1
Current: 14.84
7.3
18.1
PEG 3.51
IPSEY's PEG is ranked lower than
62% of the 278 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. IPSEY: 3.51 )
Ranked among companies with meaningful PEG only.
IPSEY' s PEG Range Over the Past 10 Years
Min: 2.85  Med: 4.84 Max: 35.98
Current: 3.51
2.85
35.98
Shiller P/E 2.21
IPSEY's Shiller P/E is ranked higher than
96% of the 170 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.66 vs. IPSEY: 2.21 )
Ranked among companies with meaningful Shiller P/E only.
IPSEY' s Shiller P/E Range Over the Past 10 Years
Min: 1.84  Med: 2.32 Max: 2.77
Current: 2.21
1.84
2.77
Current Ratio 1.64
IPSEY's Current Ratio is ranked lower than
64% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. IPSEY: 1.64 )
Ranked among companies with meaningful Current Ratio only.
IPSEY' s Current Ratio Range Over the Past 10 Years
Min: 1.39  Med: 1.92 Max: 2.33
Current: 1.64
1.39
2.33
Quick Ratio 1.38
IPSEY's Quick Ratio is ranked lower than
57% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. IPSEY: 1.38 )
Ranked among companies with meaningful Quick Ratio only.
IPSEY' s Quick Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.58 Max: 2.03
Current: 1.38
1.08
2.03
Days Inventory 133.64
IPSEY's Days Inventory is ranked lower than
58% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. IPSEY: 133.64 )
Ranked among companies with meaningful Days Inventory only.
IPSEY' s Days Inventory Range Over the Past 10 Years
Min: 133.64  Med: 160.26 Max: 176.3
Current: 133.64
133.64
176.3

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.71
IPSEY's Dividend Yield is ranked higher than
57% of the 688 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. IPSEY: 1.71 )
Ranked among companies with meaningful Dividend Yield only.
IPSEY' s Dividend Yield Range Over the Past 10 Years
Min: 1.29  Med: 2.40 Max: 4.36
Current: 1.71
1.29
4.36
Dividend Payout 0.51
IPSEY's Dividend Payout is ranked lower than
71% of the 419 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. IPSEY: 0.51 )
Ranked among companies with meaningful Dividend Payout only.
IPSEY' s Dividend Payout Range Over the Past 10 Years
Min: 0.34  Med: 0.43 Max: 80
Current: 0.51
0.34
80
Forward Dividend Yield 1.76
IPSEY's Forward Dividend Yield is ranked higher than
51% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. IPSEY: 1.76 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.93
IPSEY's Yield on cost (5-Year) is ranked higher than
52% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.86 vs. IPSEY: 1.93 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
IPSEY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.46  Med: 2.72 Max: 4.93
Current: 1.93
1.46
4.93
3-Year Average Share Buyback Ratio 0.50
IPSEY's 3-Year Average Share Buyback Ratio is ranked higher than
87% of the 462 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.90 vs. IPSEY: 0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IPSEY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.7  Med: 0.10 Max: 0.5
Current: 0.5
-12.7
0.5

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 153.89
IPSEY's Price/Net Current Asset Value is ranked lower than
97% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.29 vs. IPSEY: 153.89 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IPSEY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 10.87  Med: 56.17 Max: 343.7
Current: 153.89
10.87
343.7
Price/Tangible Book 6.35
IPSEY's Price/Tangible Book is ranked lower than
69% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.72 vs. IPSEY: 6.35 )
Ranked among companies with meaningful Price/Tangible Book only.
IPSEY' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.1  Med: 5.66 Max: 7.16
Current: 6.35
3.1
7.16
Price/Projected FCF 1.67
IPSEY's Price/Projected FCF is ranked higher than
65% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.16 vs. IPSEY: 1.67 )
Ranked among companies with meaningful Price/Projected FCF only.
IPSEY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.84  Med: 1.26 Max: 1.61
Current: 1.67
0.84
1.61
Price/Median PS Value 1.29
IPSEY's Price/Median PS Value is ranked lower than
53% of the 924 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. IPSEY: 1.29 )
Ranked among companies with meaningful Price/Median PS Value only.
IPSEY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.6  Med: 0.91 Max: 1.41
Current: 1.29
0.6
1.41
Price/Peter Lynch Fair Value 1.55
IPSEY's Price/Peter Lynch Fair Value is ranked higher than
55% of the 267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPSEY: 1.55 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
IPSEY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.41  Med: 2.20 Max: 2.99
Current: 1.55
1.41
2.99
Price/Graham Number 2.60
IPSEY's Price/Graham Number is ranked lower than
57% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.18 vs. IPSEY: 2.60 )
Ranked among companies with meaningful Price/Graham Number only.
IPSEY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.18  Med: 2.16 Max: 2.58
Current: 2.6
0.18
2.58
Earnings Yield (Greenblatt) (%) 5.50
IPSEY's Earnings Yield (Greenblatt) (%) is ranked higher than
68% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. IPSEY: 5.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IPSEY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.9  Med: 6.60 Max: 11.5
Current: 5.5
3.9
11.5
Forward Rate of Return (Yacktman) (%) 10.78
IPSEY's Forward Rate of Return (Yacktman) (%) is ranked higher than
61% of the 325 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.77 vs. IPSEY: 10.78 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
IPSEY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.3  Med: 2.60 Max: 11.5
Current: 10.78
-5.3
11.5

More Statistics

Revenue(Mil) $1332
EPS $ 0.51
Beta1.11
Short Percentage of Float0.00%
52-Week Range $11.70 - 17.45
Shares Outstanding(Mil)332.38

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 1,524 1,620
EPS($) 0.62 0.70
EPS without NRI($) 0.62 0.70

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:IPNNV.France, I7G.Germany, 0MH6.UK,
Ipsen SA was incorporated on July 28, 1998. It is a biotechnology specialty care company. It produces drugs for uro-oncology, endocrinology, neurology and hematology, and primary care. The Company's segments include Major Western European countries, including France, Italy, Spain, the United Kingdom, and Germany; Rest of Europe, including all other Western and Eastern European countries; North America, mainly including the United States; and Rest of the World, encompassing all countries.
» More Articles for IPSEY

Headlines

Articles On GuruFocus.com
Wasatch International Growth Fund Comments on Ipsen S.A. Sep 25 2015 
Wasatch International Growth Fund Q2 2015 Shareholder Letter Sep 25 2015 

More From Other Websites
Ipsen announces publication in Pediatrics of the results of the phase III randomized study showing... Jan 26 2016
Ipsen to Step Up Deal-Making, Scout for New Cancer Products Jan 19 2016
Ipsen and Galderma Expand Current Distribution Agreement for Dysport® in Aesthetic Indications to... Jan 06 2016
Ipsen SA : Overvalued relative to peers, but may deserve another look Dec 31 2015
Ipsen Announces Its Corporate Agenda for 2016 Dec 17 2015
Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology Nov 19 2015
Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology Nov 19 2015
Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311 Nov 16 2015
Ipsen: sales in the 3rd quarter and first nine months of 2015 Oct 29 2015
Ipsen SA – Value Analysis (US OTC:IPSEY) : October 28, 2015 Oct 28 2015
Telesta Therapeutics and Ipsen Announce Exclusive License Agreement for MCNA1 for the Treatment of... Oct 28 2015
Telesta Therapeutics and Ipsen announce exclusive license agreement for MCNA(1) for the treatment of... Oct 28 2015
Telesta Therapeutics and Ipsen announce exclusive license agreement for MCNA(1) for the treatment of... Oct 28 2015
Ipsen and EpiVax collaborate to produce next generation botulinum toxins Oct 26 2015
Ipsen and EpiVax collaborate to produce next generation botulinum toxins Oct 26 2015
Ipsen and EpiVax collaborate to produce next generation botulinum toxins Oct 26 2015
Ipsen Presents Additional Results from a Phase III Clinical Trial of the Investigational Use of... Oct 22 2015
Presentation of Results at the AACPDM Annual Meeting from a Phase III Trial Evaluating an... Oct 22 2015
Ipsen Announces Eight Studies of Somatuline® Depot (lanreotide) in Gastroenteropancreatic... Oct 15 2015
Stéphane Bessette is appointed Executive Vice President, Human Resources of Ipsen Oct 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK